1. Introduction {#sec1-microorganisms-08-00166}
===============

The gut serves as a reservoir of multidrug resistant (MDR) pathogens, particularly in patients who have had extensive antibiotics or a long hospital stay \[[@B1-microorganisms-08-00166]\]. While most patients who become colonized do not progress to a symptomatic infection, certain patient populations are particularly vulnerable to multidrug resistant organisms (MDRO) infections, including immunosuppressed patients \[[@B2-microorganisms-08-00166],[@B3-microorganisms-08-00166]\], travelers \[[@B4-microorganisms-08-00166]\], patients in intensive care units \[[@B5-microorganisms-08-00166]\], and those in long-term care facilities \[[@B6-microorganisms-08-00166]\]. Additionally, those who are colonized can transmit MDROs to patients vulnerable to infection in the hospital setting. Antibiotics kill subsets of commensal gut bacteria and allow for the unchecked growth of pathogenic species, causing antibiotic use to be a major risk factor for MDRO colonization and infection \[[@B7-microorganisms-08-00166]\].

Most of the microbiome-modifying therapies, or non-antibiotic therapies intended to change the bacterial makeup of the gut microbiome, are meant to replace good bacteria and out-compete pathogenic bacteria to regrow a healthy microbiome \[[@B8-microorganisms-08-00166],[@B9-microorganisms-08-00166],[@B10-microorganisms-08-00166]\]. This discussion excludes developments in the bacteriophage and lysin field, although these are also capable of modifying the gut microbiome. Fecal microbiota transplant (FMT) and donor-derived therapies are beginning to become more heavily regulated, while probiotic and prebiotic or food supplement-based strategies remain unregulated. Guidelines have been developed to use FMT safely and effectively \[[@B11-microorganisms-08-00166]\]. While some probiotics have disease-specific recommendations \[[@B12-microorganisms-08-00166]\], dosing is still difficult. While a handful of clinical trials demonstrate some efficacy for preventing colonization or transmission of MDROs, much more evidence is needed to support the use of FMT, probiotics, or prebiotics in specific patient populations with or without adjunctive therapies. This review is intended to give clinicians and clinical researchers a context for a number of cutting-edge therapies to reduce MDRO carriage and infection.

2. Methods {#sec2-microorganisms-08-00166}
==========

Clinicaltrials.gov was searched for trials containing the words "fecal", "probiotic", and "prebiotic" in the "other terms" field with the "interventional" filter selected. Additionally, the International Conference on Harmonisation Good Clinical Practice website (ichgcp.net) was searched for the same terms. The resulting 2117 studies were manually reviewed for terminology in the title, outcomes, and intervention that included any of the following terms: fecal transplant, fecal microbiota transplant, probiotic, prebiotic, antibiotic resistant, antimicrobial resistant, carbapenem, carbapenem-resistant enterobacteriaceae (CRE), vancomycin, vancomycin-resistant enterococci (VRE), extended spectrum beta-lactamase (ESBL), multidrug resistant organism, MDRO, drug resistant, *Staphylococcus aureus*, and MRSA. Additionally, referenced articles within those studies that directly addressed MDRO prevention, decolonization, or treatment were added to this review. Finally, companies that are developing non-antibiotic therapeutics that target the gut were reviewed and those that had clinical trials for MDRO treatment or prevention are included in this review.

Duplicates were removed, and 82 articles or clinical trial postings were reviewed for eligibility. Twenty-nine of these were removed for irrelevance or a lack of data regarding MDRO outcomes. Fifty-three studies were identified as measuring MDROs or MDRO colonization as the primary outcome. On pubmed.gov, studies were searched for the corresponding clinical trial numbers or study authors to find the results of trials that fit criteria within clinicaltrials.gov. While this is not an exhaustive list of every study with data on MDRO colonization, the studies selected represent interventional trials that address the use of gut microbiome-modifying therapies to alleviate the surge of MDRO colonization and infections.

3. Fecal Microbiota Transplantation {#sec3-microorganisms-08-00166}
===================================

The concept of transplanting human fecal material is more than 1700 years old, but modern medicine has only recently begun to seriously consider this therapy \[[@B13-microorganisms-08-00166]\] with rigorous clinical trials beginning in the 2010s \[[@B14-microorganisms-08-00166]\]. Despite the overwhelming number of trials without a severe adverse event, this therapy is not without risks. Typically, side effects include abdominal discomfort, fever, nausea, bloating, gas, and diarrhea. However, in June 2019, the US Food and Drug Administration (FDA) released a warning regarding FMT after two immunocompromised patients became seriously ill and one died \[[@B15-microorganisms-08-00166]\] drawing media attention \[[@B16-microorganisms-08-00166]\]. There is an ongoing controversy over whether the FDA should heavily regulate FMT, which has traditionally been performed using stool from a friend or family member under the guidance of a physician. As regulations become more rigorous, smaller stool banks will not be able to keep operating while for-profit FMT companies can financially keep up with increased testing and storage restrictions. Increased oversight will ultimately benefit this young scientific field by ensuring that patients get the safest, most effective FMT source material through an effective route of administration.

As of December 2019, 197 studies in clinicaltrials.gov were completed or actively enrolling subjects for FMT therapy, mostly for *Clostridioides difficile* infection (CDI), which was the genesis for treating MDROs with FMT \[[@B17-microorganisms-08-00166]\]. Twenty-one studies in clinicaltrials.gov are for MDRO decolonization or treatment ([Table 1](#microorganisms-08-00166-t001){ref-type="table"}). Companies that are focusing on MDRO-specific indications for their products, or who could use their products for this purpose are listed in [Table 2](#microorganisms-08-00166-t002){ref-type="table"}. Several recent reviews have discussed the usefulness of FMT for MDRO decolonization or treatment \[[@B18-microorganisms-08-00166],[@B19-microorganisms-08-00166],[@B20-microorganisms-08-00166],[@B21-microorganisms-08-00166]\]. The majority are case studies and results are mixed; some studies show complete eradication of MDROs and some show very limited changes in colonization. In a case study of a man who was colonized with 12 MDROs and received FMT for CDI, the result was partial decolonization (four MDROs 15 weeks post-FMT), fewer episodes of sepsis and infections, and less antibiotic use \[[@B22-microorganisms-08-00166]\]. While this case seemed promising, the only randomized controlled trial (RCT) directly addressing MDRO decolonization found a small, but not significant reduction in ESBL and CRE colonization after antibiotics and FMT \[[@B23-microorganisms-08-00166]\]. However, the low enrolment number and variability in both colonization and treatment methods (e.g., FMT pill at some sites and nasogastric application at others) could have contributed to the high variability in results. Additionally, there was no consistency in donor stools, with two separate institutions recruiting multiple donors, and the authors note that antimicrobial resistance (AMR) genes could have been acquired following FMT given that the screening process was not exhaustive for all possible contaminants.

Another small retrospective case-matched study of 20 patients in France showed 80% (8/10) of patients cleared CRE or CRE/*Acinetobacter* colonization 14 days after FMT versus 20% (2/10) in the control group \[[@B24-microorganisms-08-00166]\]. In other small studies (*n* = 8 to 20) with various endpoints, the effectiveness of decolonization ranged from 20% to 93% \[[@B1-microorganisms-08-00166],[@B25-microorganisms-08-00166],[@B26-microorganisms-08-00166],[@B27-microorganisms-08-00166],[@B28-microorganisms-08-00166],[@B29-microorganisms-08-00166]\]. One study by Davido et al. suggests that based on an 87% decolonization rate of VRE at three months, FMT should be further explored to combat outbreaks within hospitals \[[@B30-microorganisms-08-00166]\]. However, because only eight people were in the study, larger studies are needed to determine whether FMT could work in the face of a large outbreak of VRE infection.

Oddly, studies of probiotics have more consistently used placebo controls than FMT studies, as discussed in the probiotics section and shown in [Table 1](#microorganisms-08-00166-t001){ref-type="table"} and [Table 3](#microorganisms-08-00166-t003){ref-type="table"}. More thorough RCTs are needed to determine the utility of FMT for specific MDROs using single-donor source material.

4. Probiotics and Prebiotics {#sec4-microorganisms-08-00166}
============================

Probiotics are not federally regulated unless companies undergo regulatory compliance checks on their own or want to market their product as a drug. Anyone can sell and market probiotics regardless of whether the bacteria are alive or even present. Most probiotic companies do not genotype their bacteria or assess the presence of AMR genes \[[@B32-microorganisms-08-00166]\], although Cabana et al. noted that reputable companies follow good manufacturing procedures and test for AMR genes, which can be verified by consumers \[[@B33-microorganisms-08-00166]\]. While the debate over the safety of probiotic use in healthy individuals is ongoing, several clinicians and researchers have voiced concern over probiotic use in immunocompromised populations \[[@B34-microorganisms-08-00166],[@B35-microorganisms-08-00166],[@B36-microorganisms-08-00166],[@B37-microorganisms-08-00166]\]. Side effects, even in healthy populations, can include infections, immune stimulation, production of harmful byproducts, and the spread of AMR genes \[[@B38-microorganisms-08-00166]\]. Because of the lack of regulation for these products, bacteria that are not listed on the label can be present in the product and cause unexpected side effects. Regardless of safety, only a few health conditions have been studied for efficacy rigorously enough to garner a recommendation by expert clinicians \[[@B12-microorganisms-08-00166]\]. Most prominent in these recommendations for gastrointestinal (GI) disorders, immune response, and liver disease are lactobacillus GG (LGG) and VSL\#3, which are also the most extensively studied for MDRO indications thus far. It should be noted that the product, VSL\#3, developed by Claudio De Simone at VSL Pharmaceuticals is now sold as VISBIOME® and is materially different from the product that VSL still sells as VSL\#3 \[[@B39-microorganisms-08-00166]\]. Because of this covert change in formulation, several research studies of VSL\#3 were terminated, and some countries and retailers pulled VSL\#3 from circulation.

Currently, 20 studies have tested or are testing probiotics, and one is testing a prebiotic for MDRO decolonization or prevention ([Table 3](#microorganisms-08-00166-t003){ref-type="table"}). Ten of these studies have shown no difference in colonization following probiotic therapy in subjects who were healthy volunteers \[[@B40-microorganisms-08-00166]\], methicillin-resistant *S.aureus* (MRSA)-colonized \[[@B41-microorganisms-08-00166]\], VRE-colonized \[[@B42-microorganisms-08-00166],[@B43-microorganisms-08-00166]\], ESBL-colonized \[[@B31-microorganisms-08-00166]\], MDR *Escherichia coli*-colonized \[[@B44-microorganisms-08-00166]\], a mix of MDRO colonization \[[@B45-microorganisms-08-00166]\], on antibiotics or a ventilator \[[@B46-microorganisms-08-00166]\], preterm infants \[[@B47-microorganisms-08-00166]\], or travelers \[[@B48-microorganisms-08-00166]\]. While these results can seem dismal, most studies have used LGG or *L. reuteri* singularly, so much more remains to be explored.

One striking outlier is a study done by Manley et al., in 2007, in which pasteurized yogurt with and without LGG was administered \[[@B49-microorganisms-08-00166]\]. Of the 27 patients enrolled, 23 subjects completed the trial and 11/11 (100%) in the treatment arm were negative for VRE colonization eight weeks after initiation of the treatment as compared with 1/12 (9%) in the control arm. Eight of the control patients were then crossed over to receive LGG treatment, and all of them cleared VRE within four weeks. While this study seemed extremely promising, a larger trial by Warrack et al. that started the following year concluded that there was no difference in VRE colonization rates in recently infected patients who used 6 grams of LGG. Colonization status was only available for a portion of the participants (36/50), and an even smaller number were colonized at the beginning of the study (9/36) \[[@B42-microorganisms-08-00166]\]. At four weeks, two additional patients in the control arm had become colonized and one in the treatment group had been cleared of VRE. Despite these findings, the same group found some efficacy of a particular LGG strain called HN001. Supplementation with *L. rhamnosus* HN001 reduced MRSA colonization, but these results were mainly restricted to gut decolonization, not nasal or other sites \[[@B41-microorganisms-08-00166],[@B50-microorganisms-08-00166]\]. In a study of 61 children colonized with VRE, one group found that LGG temporarily decolonized patients, but ultimately some would become recolonized after treatment stopped \[[@B51-microorganisms-08-00166]\].

Ongoing trials include a large study at Taipei Medical University that is examining the efficacy of a probiotic cocktail on VRE colonization (NCT03822819), and unlike the Warrick study \[[@B42-microorganisms-08-00166]\], the researchers directly recruit patients who are colonized with VRE. Another trial examining the efficacy of *Bifidobacterium infantis* in women with recurrent MDRO urinary tract infections is ongoing at Ochsner Medical Center (NCT03644966), but neither of the authors are involved in that work.

In a departure from probiotics, Kaleido Biosciences is assessing KB109 for its ability to clear VRE, ESBL, or CRE colonization (NCT03944369). Their technology consists of a library of nondigestible glycans branded as Microbiome Metabolic Therapies (MMT™) that can be assessed in thousands of patient samples *ex vivo* for a compounds ability to encourage the growth of certain bacteria that outcompete unhealthy bacteria or inflammatory bacteria (reviewed in \[[@B52-microorganisms-08-00166]\]). Some of the assays that support the use of these compounds for eliminating MDRO carriage were recently presented \[[@B53-microorganisms-08-00166]\]. Inulin, an oligosaccharide that is undigestible by humans but fermented by bacteria in the gut, is currently being used in an ongoing clinical trial at Columbia University (NCT03865706). Typically, prebiotics cause moderate gastrointestinal issues like bloating and gas, but are unlikely to increased AMR genes because they are not made with live bacteria. Thus, prebiotics could be a valuable therapeutic tool in the fight against MDRO colonization and infection, but their efficacy remains to be determined.

5. Clinical Considerations and the Future of Microbiome-Modifying Bacterial Therapies. {#sec5-microorganisms-08-00166}
======================================================================================

Clinical use of FMT has been somewhat regulated; the FDA has exercised enforcement discretion regarding the investigation of new drug requirements for CDI in the face of overwhelming evidence that FMT is highly effective in otherwise treatment-resistant or recurrent CDI. Guidelines published regarding the implementation of FMT for CDI \[[@B11-microorganisms-08-00166]\] could translate to use for other diseases. However, there is a lack of diagnostic capacity or even a clear understanding of what constitutes a healthy microbiome. It is difficult to determine whether FMT directly causes reliable changes in the microbiome or if specific, rationally designed therapies would work more effectively in such a complex system. Additionally, many studies use related donors, a multitude of donors, or inconsistent screening processes, making it difficult to determine if fecal transplant from any healthy donor is effective or if more specific elements of FMT are necessary for successful engraftment. Recently, super-donors have drawn attention in the field \[[@B54-microorganisms-08-00166]\], and in the case of irritable bowel syndrome, a super-donor could make the difference as to whether FMT works or not \[[@B55-microorganisms-08-00166]\]. In this same vein, perhaps therapies could replicate the bacterial consortiums found in super-donor individuals and be used in a standardized manner to compare the therapy to decolonize different organisms. In the clinical world, a diagnostic to help determine when patients are likely to succeed or fail with various FMT products or when they would need additional doses could significantly increase the use and consistency of FMT therapy. In the basic science world, a commercially available assay, such as the platform that Kaleido uses to test the output of various combinations of bacteria, could accelerate new strategies for FMT, prebiotic, and probiotic approaches, and even precision medicine.

Overall, the challenges with clinical implementation of probiotic therapies for MDROs or other diseases stem from a lack of regulation and insufficient scientific studies to determine appropriate dosing or extensively compare strains and strain combinations for MDRO decolonization. Some new studies in animals show that whether the probiotics are living or dead may not even matter \[[@B56-microorganisms-08-00166]\], and that there may be more efficacy in simply using bacterial byproducts for therapy. Piewngam et al. found that people colonized with *Bacillus* from their diet had zero incidence of colonization with MRSA, which was markedly different from that of the 25% of people without *Bacillus* who were colonized in the GI tract and nasal cavity. Through in vitro testing, they discovered that fengycins, a class of cyclic lipopeptides, are produced by *Bacillus* and directly inhibit the growth of MRSA \[[@B57-microorganisms-08-00166]\]. While this type of therapy has yet to be developed for a clinical trial, it signifies the value of more rigorous preclinical assessment of probiotics to pinpoint the most efficacious mechanisms of action.

Microbiome-modifying therapies would benefit from robust RCTs that are laser focused on a specific pathogen or patient population and a rational dosing regimen. An equivalent assessment to pharmacokinetic and pharmacodynamic studies, such as daily sequencing of stool samples to assess engraftment, would assist in determining dose and frequency effects, and commercial companies (e.g., CosmosID, CoreBiome, and Viome) have optimized shotgun sequencing of the whole microbiome to be extremely cost effective. Furthermore, if any microbiome therapy is going to be used for MDRO treatment or prevention, clear guidelines for use in gram-positive versus gram-negative infections and various mechanisms of resistance are necessary, as FMT has not been particularly efficacious with MDR gram-negative bacteria so far \[[@B44-microorganisms-08-00166],[@B45-microorganisms-08-00166]\]. Some have speculated that FMT could be less effective for ESBL decolonization, although the mechanism by which this is possible has yet to be defined \[[@B25-microorganisms-08-00166],[@B58-microorganisms-08-00166]\]. Finally, research needs to show more than a lack of inferiority; rather, studies should be designed to measure outcomes where FMT or probiotic therapies could show an advantage beyond acute treatment (e.g., reduced readmission, fewer subsequent infections, and fewer long-term complications). A 2019 study from Finland has suggested that extensive treatment with antibiotics can induce Parkinson disease 10 to 15 years later \[[@B59-microorganisms-08-00166]\], and although long-term studies are costly, perhaps the long-term implications are worth considering for lengthy therapy options.

6. Conclusions {#sec6-microorganisms-08-00166}
==============

Given a handful of positive results of bacterial therapy for MDRO colonization, this strategy is certainly worth pursuing in a systematic rigorous way. Studies that include single-source FMT or standard, regulated probiotic therapies for specific MDROs enable physicians and hospital systems to make rational decisions about how to best handle colonized or infected patients and healthcare workers. However, these treatments alone will not solve the issue of antibiotic resistance. Other therapies including bacteriophage \[[@B60-microorganisms-08-00166],[@B61-microorganisms-08-00166]\], lytic enzymes \[[@B62-microorganisms-08-00166]\], novel cleaning techniques \[[@B63-microorganisms-08-00166]\], repurposed drugs with antibiotic activity \[[@B64-microorganisms-08-00166]\], and bacterial byproducts \[[@B57-microorganisms-08-00166]\] should be further developed. With enough duplicity in treatment options, hopefully physicians will be able to prevent global outbreaks of treatment-resistant infections.
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microorganisms-08-00166-t001_Table 1

###### 

Clinical trials for fecal microbiota transplantation (FMT) that directly target multidrug resistant organisms (MDRO) colonization or infection.

  Year      Sponsor                                    Product                           Placebo/Controlled   Clinical Stage   Target                     Number of Patients   NCT Number               Effect   Conclusions                                       Reference
  --------- ------------------------------------------ --------------------------------- -------------------- ---------------- -------------------------- -------------------- ------------------------ -------- ------------------------------------------------- ------------------------------------
  2015      Washington University School of Medicine   FMT (enema)                       no                   Phase 1          MDRO infections            20                   NCT02312986                       Ongoing                                           
  2015      Jinling Hospital, China                    FMT (nasointestinal tube)         no                   N/A              MRSA                       10                   NCT02390622                       Ongoing                                           
  2016      University of Miami                        FMT (enema)                       no                   Phase 1          MDRO                       20                   NCT02816437                       Ongoing                                           
  2016      Cepheid/ Emory University                  Allogeneic FMT                    yes                  Phase 1          MDRO                       20                   NCT02922816                       Ongoing                                           
  2017      Raymond Poincaré Teaching Hospital         FMT (nasoduodenal tube)           no                   N/A              CRE/VRE                    8                    EudraCT 2014-003048-11   ++       3/8 patients decolonized after 3 months           \[[@B27-microorganisms-08-00166]\]
  2017      Medical University of Warsaw               intraduodenal FMT                 no                   N/A              MDRO                       20                   NCT02461199              +++      15/20 (75%) complete decolonization               \[[@B1-microorganisms-08-00166]\]
  2017      Raymond Poincaré Teaching Hospital         FMT (nasoduodenal tube)           no                   N/A              VRE                        8                    NCT03029078              ++++     87.5% eradication at 3 months                     \[[@B26-microorganisms-08-00166]\]
  2017      Microbiome Health Research Institute       Autologous FMT                    yes                  Phase 1          MDRO                       4                    NCT03061097                       Completed. No results available.                  
  2017      Microbiome Health Research Institute       FMT (pill)                        yes                  Phase 2          VRE                        9                    NCT03063437                       Completed. No results available.                  
  2017      Seattle Children's Hospital                FMT                               no                   Phase 1          ESC-R Enterobacteriaceae   20                   NCT02543866                       Ongoing                                           
  2018      Academic Medical Centre, Amsterdam         FMT                               no                   N/A              ESBL                       15                   ISRCTN48328635           ++       20-40% clearance with one or two FMTs             \[[@B29-microorganisms-08-00166]\]
  2018      Versailles Saint-Quentin University        FMT (nasoduodenal tube)           no                   N/A              CRE/VRE                    17                                            +++      4/8 CRE clearance 7/8 VRE clearance at 3 months   \[[@B28-microorganisms-08-00166]\]
  2018      Rebiotix                                   RBX2660                           no                   Phase 1/2        Recurrent MDRO UTIs        60                   NCT03367910                       Ongoing                                           
  2018      Chinese University of Hong Kong            FMT                               yes                  Phase 2          CRE/VRE                    40                   NCT03479710                       Ongoing                                           
  2018      Rambam Health Care Campus                  FMT                               no                   N/A              CRE                        60                   NCT03167398                       Ongoing                                           
  2019      University Hospital, Ghent                 Allogenic vs Autologous FMT       yes                  Phase 2/3        Any MDRO                   150                  NCT04188743                       Unknown                                           
  2019      University Health Network, Toronto         FMT                               yes                  Phase 2/3        CRE                        40                   NCT03802461                       Ongoing                                           
  2019      Rambam Health Care Campus                  FMT                               no                   N/A              CRE                        60                   NCT03391674                       Ongoing                                           
  2019      University of British Columbia             FMT                               no                   N/A              Any MDRO                   90                   NCT04181112                       Ongoing                                           
  2019      Vancouver Island Health Authority          FMT                               no                   N/A              Any MDRO                   50                   NCT03834051                       Ongoing                                           
  2019      Raymond Poincaré Teaching Hospital         FMT (nasoduodenal tube)           no                   N/A              VRE                        8                                             ++++     87% decolonization after 3 months                 \[[@B30-microorganisms-08-00166]\]
  2019      Saint Antoine Hospital, Paris              FMT (enema or nasogastric tube)   no                   N/A              CRE/VRE                    10                                            +++      Generally safe and effective in these patients    \[[@B25-microorganisms-08-00166]\]
  2019      University of British Columbia             FMT (enema) +/− antibiotic        no                   N/A              MDROs                      90                   NCT04181112                       Ongoing                                           
  2019      Geneva University Hospitals                FMT (pill and nasopharengeal)     yes                  Phase 2          ESBL/CPE                   39                   NCT02472600              \+       Slight reduction in colonization                  \[[@B23-microorganisms-08-00166]\]
  2020      Rambam Health Care Campus                  FMT (pills)                       yes                  Phase 2/3        CRE                        60                   NCT04146337                       Not yet recruiting                                
  2022 \*   University of Wisconsin, Madison           FMT (pills)                       yes                  Phase 2          CRE/VRE                    90                   NCT03643887                       Not started                                       

Fecal microbiota transplantation (FMT), *Lactobacillus rhamnosus* GG (LGG), vancomycin-resistant enterococci (VRE), methicillin-resistant *Staphylococcus aureus* (MRSA), multidrug resistant (MDR), *Lactobacillus casei rhamnosus* (Lcr35), carbapenem resistant *Klebsiella Pneumonia* (CRKP), extended spectrum beta-lactamases (ESBL), carbapenem-resistant enterobacteriaceae (CRE), extended-spectrum resistant (ESC-R), urinary tract infections (UTIs). \<25% improvement (+), 26% to 50% improvement (++), 51% to 75% improvement (+++), 76% to 100% improvement (++++). \* Projected start date.

microorganisms-08-00166-t002_Table 2

###### 

Companies developing microbiome-modifying therapies that could be used for MDROs.

  Company             Product Name or Prefix         Therapy Type                                Proposed Mechanism                              Trials Specifically for MDRO
  ------------------- ------------------------------ ------------------------------------------- ----------------------------------------------- ----------------------------------------
  Rebiotix            RBX2660                        FMT (enema)                                 Displacement of MDRO                            Phase 1/2
  Kaleido             KB109                          prebiotic                                   Feed healthy bacteria to out-compete MDRO       Clinical Food Study
  ExeGi               Visbiome (US), Vivomixx (EU)   probiotic                                   Displacement of MDRO                            Yes \[[@B31-microorganisms-08-00166]\]
  Vedanta             VE707                          rationally selected microbiota              Displacement of MDRO                            Preclinical
  SciBac              SCB                            engineered probiotic                        Transfer of plasmids to enhance good bacteria   Preclinical
  Rise Therapeutics   R                              delivery technology for protein therapies   Immune modulation                               Preclinical
  Finch               CP & FIN                       FMT, rationally selected microbiota         Displacement of MDRO                            No
  OpenBiome           unbranded pills                FMT (pills)                                 Displacement of MDRO                            No
  Seres               SER                            FMT, rationally selected microbiota         Displacement of MDRO                            No
  Evelo               EDP                            monoclonal microbials                       Immune modulation                               No
  Enterome            EB                             small molecule                              Immune modulation                               No
  PureTech Health     numerous                       hydrogel                                    Physical clearing of gut                        No
  Atterx              C-1205                         lyophilized *E. coli*                       Prevents growth of MDRO                         On website, no NCT
  Atterx              GN-4474                        bacterial conjugation + killer plasmid      Transfer of toxic plasmid to target bacteria    On website, no NCT

microorganisms-08-00166-t003_Table 3

###### 

Clinical trials for probiotics and prebiotics that directly target MDRO colonization or infection.

  Treatment Type                      Year                                            Sponsor                            Product                   Placebo/Controlled   Clinical Stage                 Target               Number of Patients   NCT Number    Effect                                           Conclusions                          Reference
  ----------------------------------- ----------------------------------------------- ---------------------------------- ------------------------- -------------------- ------------------------------ -------------------- -------------------- ------------- ------------------------------------------------ ------------------------------------ ------------------------------------
  Probiotic (live bacteria product)   2000                                            Karolinska Institutet              probiotic or vancomycin   no                   N/A                            Healthy volunteers   40                                 0                                                No effect on VRE colonization        \[[@B40-microorganisms-08-00166]\]
  2003                                Tufts Medical Center                            LGG or Culturelle                  yes                       Phase 1              VRE                            11                   NCT00756262          0             No effect on VRE colonization                    \[[@B43-microorganisms-08-00166]\]   
  2003                                University Hospital, Clermont-Ferrand           Lcr35                              unclear                   N/A                  MDR *Pseudomonas aeruginosa*   400                  NCT00621803                        Terminated                                                                            
  2007                                Austin Health                                   yogurt with LGG                    yes                       N/A                  VRE                            27                                        ++++          100% cleared                                     \[[@B49-microorganisms-08-00166]\]   
  2007                                Oregon Health and Science University            yogurt drink                       yes                       N/A                  VRE                            8                    NCT00591474                        Terminated                                                                            
  2008                                University of Wisconsin, Madison                VSL\#3                             yes                       Phase 2              VRE                            50                   NCT00933556          0             No effect on VRE but tolerated probiotics well   \[[@B42-microorganisms-08-00166]\]   
  2008                                Hadassah Medical Organization                   VSL\#3                             yes                       Phase 1/2            CRKP                           60                   NCT00722410                        Unknown                                                                               
  2009                                University Hospital, Clermont-Ferrand           Lcr35                              yes                       Phase 4              VRE                            24                   NCT00437580                        Unknown                                                                               
  2009                                Bio-K Plus International                        *L. acidophilus* CL1285®           yes                       Phase 2              MRSA                           146                  NCT00941356                        Unknown                                                                               
  2010                                University of Wisconsin, Madison                *L. rhamnosus* HN001               yes                       Phase 2              MRSA                           49                   NCT01112995          \+            30-50% reduction at 4 weeks                      \[[@B41-microorganisms-08-00166]\]   
  2011                                University of Otago                             *E. coli* Nissle 1917 (Mutaflor)   yes                       N/A                  MDR *E. coli*                  69                                        0             No effect                                        \[[@B44-microorganisms-08-00166]\]   
  2011                                Baskent University                              *L. reuteri*                       yes                       N/A                  Any MDRO                       76                   NCT02178267          0             No difference in acquisition of MDROs            \[[@B47-microorganisms-08-00166]\]   
  2011                                Poznan University of Medical Sciences           LGG                                yes                       N/A                  VRE (children)                 61                                        +/-           Temporary elimination of VRE                     \[[@B51-microorganisms-08-00166]\]   
  2011                                University of Wisconsin, Madison                *L. rhamnosus* HN001               yes                       Phase 2              MRSA                           113                  NCT01321606          \+            Reduced odds of MRSA colonization of the gut     \[[@B50-microorganisms-08-00166]\]   
  2012                                Washington University School of Medicine/ CDC   Culturelle (LGG)                   yes                       Phase 4              Any MDRO                       103                  NCT01551186          0             No effect of acquisition or loss of any MDROs    \[[@B46-microorganisms-08-00166]\]   
  2014                                Washington University School of Medicine/ CDC   Culturelle (LGG)                   yes                       Phase 4              Any MDRO                       87                   NCT02046512          0             No effect of acquisition or loss of any MDROs    \[[@B46-microorganisms-08-00166]\]   
  2014                                Hospital Universitario La Paz                   Lactitol and Lactobacillus         no                        Phase 2              CRKP                           20                   NCT02307383                        Suspended (Unable to recruit patients)                                                
  2016                                Universidade de São Paulo                       symbiotic product                  yes                       N/A                  MDR Gram-negative              101                                       0             Not effective for decolonizing                   \[[@B45-microorganisms-08-00166]\]   
  2017                                Lund University/ ExeGi                          Vivomixx (EU) /Visbiome (US)       yes                       N/A                  ESBL                           80                   NCT03860415          0             Vivomixx® was not superior to placebo            \[[@B31-microorganisms-08-00166]\]   
  2018                                Procter and Gamble/ Ochsner Health System       *B. infantis*                      yes                       N/A                  MDR urinary tract infections   100                  NCT03644966                        Ongoing                                                                               
  2018                                Hvidovre University Hospital                    Lactobacillus                      yes                       N/A                  VRE                            162                  NCT03560700                        Not yet recruiting                                                                    
  2019                                Aarhus University Hospital                      LGG                                yes                       N/A                  MDR Enterobacteriaceae         61                                        0             No difference in colonization                    \[[@B48-microorganisms-08-00166]\]   
  2019                                Hospital Italiano de Buenos Aires               probiotic                          yes                       N/A                  CRE                            228                  NCT03967301                        Ongoing                                                                               
  2019                                Taipei Medical University /Delta Electronics    probiotic cocktail                 yes                       N/A                  VRE                            100                  NCT03822819                        Ongoing                                                                               
                                      2020                                            University of Bergen               Labinic (R) probiotic     yes                  Phase 3                        ESBL                 2000                 NCT04172012                                                    Ongoing                              
  Prebiotic/food                      2019                                            Columbia University                Inulin                    yes                  Phase 2                        Any MDRO             90                   NCT03865706                                                    Ongoing                              
  2019                                Kaleido Biosciences                             KB109                              yes                       N/A                  VRE, ESBL, or CRE              64                   NCT03944369                        Ongoing                                                                               

Fecal Microbiota Transplant (FMT), *Lactobacillus rhamnosus* GG (LGG), vancomycin-resistant enterococci (VRE), methicillin-resistant *S. aureus* (MRSA), multidrug resistant (MDR), carbapenem-resistant enterobacteriaceae (CRE), extended spectrum beta-lactamases (ESBL), *Lactobacillus casei rhamnosus* (Lcr35), and carbapenem resistant *Klebsiella Pneumonia* (CRKP). No effect (0), mixed results (+/−), \<25% improvement (+), 76% to 100% improvement (++++)
